Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results

    CALGARY, May 5 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:  ONCY)
("Oncolytics" or the "Company") today announced its financial results for the
three-month period ended March 31, 2009.
    "The first quarter of 2009 was highlighted by the announcement of very
positive results in several of our combination REOLYSIN(R) clinical trials,"
said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to
report clinical benefit in the majority of patients treated with REOLYSIN in
combination with chemotherapy or radiation, paving the way for our pivotal
program to begin this year."

    Selected First Quarter Highlights:

    -  Announced positive interim results from a U.K. Phase I/II combination
       REOLYSIN and paclitaxel/carboplatin trial for patients with advanced
       head and neck cancers. Of 12 evaluable patients, five patients had
       partial responses (PR) and four patients had stable disease (SD), for
       a clinical benefit rate (complete response + partial response + stable
       disease) of 75%;

    -  Announced positive results from a U.K. combination REOLYSIN and
       docetaxel trial for patients with a variety of advanced cancers.
       Fifteen of the 17 evaluable patients experienced SD or better,
       including two PR, three minor responses and 10 SD, giving a clinical
       benefit rate of 88%;

    -  Completed enrolment in a U.K. combination REOLYSIN and gemcitabine
       clinical trial. Of the ten patients evaluable for response, two
       patients (breast and nasopharyngeal) had PRs and five patients had SD,
       for a clinical benefit rate of 70%;

    -  Started patient enrolment in a U.S. Phase 2 Combination REOLYSIN and
       paclitaxel/carboplatin clinical trial for patients with non-small cell
       lung cancer with K-RAS or EGFR-activated tumours. Eligible patients
       include those who have not received chemotherapy treatment for their
       metastatic or recurrent disease;

    -  Started patient enrolment in a U.K. translational clinical trial
       investigating REOLYSIN in patients with metastatic colorectal cancer;

    -  Announced a multi-trial clinical research collaboration with the
       Cancer Therapy & Research Center at the University of Texas Health
       Science Center involving up to five, open-label, Phase 2 studies
       exploring the use of REOLYSIN(R) in combination with chemotherapy for
       various cancer indications. These indications are expected to include
       melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS
       mutated colorectal cancers in combination with standard

    Latest Highlights

    Subsequent to quarter end, the Company announced:

    -  Positive results of a U.K. Phase II REOLYSIN and radiation combination
       clinical trial. Of 14 evaluable patients, 13 patients had SD or better
       in the treated target lesions, including four PRs and two minor
       responses, for a clinical benefit rate of 93% in the treated lesions;

    -  The successful acquisition of PrivateCo., an inactive private company
       with net cash of $2.1 million; and

    -  A proposed public offering consisting of up to 3.45 million units at
       $2.00 per unit, for gross proceeds of up to $6.9 million.

                           Oncolytics Biotech Inc.


    As at,
                                                    March 31,    December 31,
                                                      2009          2008
                                                        $             $
    Cash and cash equivalents                        7,366,481     7,429,895
    Short-term investments                           1,925,600     5,846,634
    Accounts receivable                                 68,411        86,322
    Prepaid expenses                                   101,025       179,668
                                                     9,461,517    13,542,519

    Property and equipment                             249,971       263,926

    Intellectual property                               90,375       180,750

                                                     9,801,863    13,987,195

    Accounts payable and accrued liabilities         4,273,538     4,534,111

    Shareholders' equity
    Share capital
      Authorized: unlimited number of common shares
      Issued: 43,855,748 (December 31, 2008 -
       43,830,748)                                  95,256,174    95,234,924
    Warrants                                         3,425,110     3,425,110
    Contributed surplus                             13,361,438    13,349,801
    Deficit                                       (106,514,397) (102,556,751)
                                                     5,528,325     9,453,084

                                                     9,801,863    13,987,195

                           Oncolytics Biotech Inc.

                             COMPREHENSIVE LOSS

                                     Three Month   Three Month   Cumulative
                                       Period        Period    from inception
                                       Ending        Ending       on April 2,
                                      March 31,     March 31,   1998 to March
                                        2009          2008         31, 2009
    	                                      $             $             $

    Rights revenue                             -             -       310,000
    Research and development           2,812,655     2,393,397    77,344,432
    Operating                            986,764     1,050,894    25,823,789
    Stock-based compensation              11,637        19,593     4,780,481
    Foreign exchange loss                 56,035         9,262       645,462
    Amortization - intellectual
     property                             90,375        90,375     3,524,625
    Amortization - property and
     equipment                            17,304        11,186       514,455
                                       3,974,770     3,574,707   112,633,244

    Loss before the following          3,974,770     3,574,707   112,323,244

    Interest income                      (17,124)     (180,334)   (6,551,129)

    Gain on sale of BCY LifeSciences Inc.      -             -      (299,403)

    Loss on sale of Transition
     Therapeutics Inc.                         -             -     2,156,685

    Loss before income taxes           3,957,646     3,394,373   107,629,397

    Future income tax recovery                 -             -    (1,115,000)
    Net loss and comprehensive loss
     for the period                    3,957,646     3,394,373   106,514,397

    Basic and diluted loss per share       (0.09)        (0.08)

    Weighted average number of shares
     (basic and diluted)              43,849,637    41,180,748

                           Oncolytics Biotech Inc.


                                     Three Month  Three Month       from
                                       Period        Period     inception on
                                       Ending        Ending     April 2, 1998
                                      March 31,     March 31,    to March 31,
                                        2009          2008          2009
                                          $             $             $
    Net loss for the period           (3,957,646)   (3,394,373) (106,514,397)
    Add / (deduct) non-cash items
      Amortization - intellectual
       property                           90,375        90,375     3,524,625
      Amortization - property and
       equipment                          17,304        11,186       514,455
      Stock-based compensation            11,637        19,593     4,780,481
      Other non-cash items                     -             -     1,383,537
    Net change in non-cash working
     capital                            (164,019)       24,681     4,104,102
    Cash used in operating activities (4,002,349)   (3,248,538)  (92,207,197)

    Purchase of property and equipment    (3,349)       (2,665)     (817,093)
    Purchase of short-term investments    (8,966)     (137,187)  (49,425,830)
    Redemption of short-term
     investments                       3,930,000     4,000,000    47,081,746
    Investment in BCY LifeSciences Inc.        -             -       464,602
    Investment in Transition
     Therapeutics Inc.                         -             -     2,532,343
    Cash provided by (used in)
     investing activities              3,917,685     3,860,148      (164,232)
    Proceeds from exercise of warrants
     and stock options                    21,250             -    15,322,318
    Proceeds from private placements           -             -    38,137,385
    Proceeds from public offerings                           -    46,278,207
    Cash provided by financing
     activities                           21,250             -    99,737,910
    Net increase (decrease) in cash
     and cash equivalents during the
     period                              (63,414)      611,610     7,366,481
    Cash and cash equivalents,
     beginning of the period           7,429,895     6,715,096             -
    Cash and cash equivalents, end of
     the period                        7,366,481     7,326,706     7,366,481

    To view the 2009 First Quarter Report which includes the Consolidated
Financial Statements, related Notes to Consolidated Financial Statements, and
Management's Discussion and Analysis, please see the Company's first quarter
filings which will be available on www.sedar.com and on

    About Oncolytics Biotech Inc.

    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN, its proprietary formulation of the human reovirus, alone and
in combination with radiation or chemotherapy. For further information about
Oncolytics please visit www.oncolyticsbiotech.com

    This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's belief as to the potential
of REOLYSIN as a cancer therapeutic; the Company's expectations as to the
success of its research and development programs in 2009 and beyond, the
Company's planned operations, the value of the additional patents and
intellectual property; the Company's expectations related to the applications
of the patented technology; the Company's expectations as to adequacy of its
existing capital resources; the design, timing, success of planned clinical
trial programs; and other statements related to anticipated developments in
the Company's business and technologies involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue research and development projects, the efficacy of REOLYSIN as a
cancer treatment, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize REOLYSIN,
uncertainties related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by applicable

    %SEDAR: 00013081E

For further information:

For further information: Oncolytics Biotech Inc., Cathy Ward, 210, 1167
Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403)
283-0858, cathy.ward@oncolytics.ca; The Equicom Group, Nick Hurst, 325, 300
5th Ave. SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403)
237-6916, nhurst@equicomgroup.com; The Investor Relations Group, Erika Moran,
11 Stone St, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212)
825-3229, emoran@investorrelationsgroup.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890